Top Industry Leaders in the Primary Ciliary Dyskinesia Market
Parion Pharmaceuticals announces positive results from a Phase 2 clinical trial of inhaled idrevloride with hypertonic saline for treating PCD, demonstrating improvements in lung function and mucociliary clearance
Shire (Takeda) receives FDA approval for Pulmozyme® (dornase alfa), expanding treatment options for PCD patients struggling with chronic respiratory infections.Aerocrine introduces the SpiroSonic® NO Meter, a portable device for measuring nitric oxide levels in exhaled breath, potentially aiding in PCD diagnosis and monitoring
The PCD Foundation partners with pharmaceutical companies and research institutions to accelerate clinical trials and development of new treatments for PCD.
Cystic Fibrosis Foundation Therapeutics (CFFT) collaborates with researchers to explore potential synergies between PCD and cystic fibrosis therapies, benefiting both patient populations.
List of Primary Ciliary Dyskinesia Key Companies in the Market
- AstraZeneca
- Boehringer Ingelheim GmbH
- GlaxoSmithKline
- Novartis AG
- Pfizer Inc.
- Teva UK Limited
- Masimo Corporation (U.S.)
- BD (U.S.)
- Portex Division of Smith Industries Medical System
- Teruma Medical Corporation
- HTL STREFA SA
- Greinier Bio One International GmBH.
- Hoffman La Roche AG
- Bayer AG.
- Acare Technology Co.
- Medline Industries Inc.Ltd.
- Hill-Rom Holdings Inc.
- Allied Healthcare Inc.
- Rotech Healthcare Inc